Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Lizinna 250microgram/35microgram tablets
0703010G0BGAAAC
|
Lizinna | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 11,070 |
|
Cilique 250microgram/35microgram tablets
0703010G0BHAAAC
|
Cilique | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 10,861 |
|
Ethinylestradiol 35microgram / Norgestimate 250microgram tab
0703010G0AAACAC
|
Combined ethinylestradiol 35mcg | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 8,166 |
|
Brevinor 500microgram/35microgram tablets
0703010G0BCAAAA
|
Brevinor | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 3,497 |
|
Norimin 1mg/35microgram tablets
0703010G0BDAAAB
|
Norimin | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 851 |
|
Ethinylestradiol 35microg / Norethisterone 500microg tab
0703010G0AAAAAA
|
Combined ethinylestradiol 35mcg | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 733 |
|
Ethinylestradiol 35microgram / Norethisterone 1mg tablets
0703010G0AAABAB
|
Combined ethinylestradiol 35mcg | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 189 |
|
Cilest 35microgram/250microgram tablets
0703010G0BFAAAC
|
Cilest | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 47 |
|
Ovysmen 500microgram/35microgram tablets
0703010G0BBAAAA
|
Ovysmen | Combined ethinylestradiol 35mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.